Drug information of Frovatriptan


Drug group:

Mechanism of effect

Selective agonist for serotonin (5-HT1B and 5-HT1D receptors) in cranial arteries; causes vasoconstriction and reduces sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine.


Half-life: 26 hr

Peak plasma time: 2-4 hr

Metabolism: CYP1A2

Distribution: 4.2 L/kg (male); 3 L/kg (female)

Protein binding: 15%

Bioavailability: 20% (male); 30% (female)

Excretion: Feces (62%); urine (32%)

Drug indications



2.5 mg PO at onset; may repeat once after 2 hr

Not to exceed 7.5 mg/day

Drug contraindications

-Hypersensitivity, severe hepatic or renal impairment, migraine prophylaxis

-Ischemic heart disease, uncontrolled HTN, hemiplegic or basilar migraines, cluster headache, cerebrovascular syndromes, PVD

-Do not use within 24 hr of another 5-HT1 agonist or ergot derivative, or within 2 weeks of MAOIs

Side effects

Flushing , hot or cold flashes , chest pain , palpitations, Dizziness , fatigue ,headache , paresthesia , drowsiness , anxiety , dysesthesia , hypoesthesia , insomnia , pain, Diaphoresis ,Xerostomia , nausea , dyspepsia , abdominal pain , diarrhea , vomiting, Musculoskeletal pain, Visual disturbance, Tinnitus ,Rhinitis , sinusitis

Droxidopa ,Ergot Derivatives ,Monoamine Oxidase Inhibitors ,Serotonergic Agents ,SUMAtriptan


-Serious cardiac and cerebrovascular events, including cerebral hemorrhage, subarachnoid hemorrhage, stroke, acute MI, arrhythmias, and death reported within a few hours after administration

-Chest discomfort and jaw or neck tightness reported infrequently following intranasal administration

-Serotonin syndrome may occur, particularly when coadministered with SSRIs

-Not for use with unrecognized Coronary artery disease as predicted by risk factors (eg, hypertension, hypercholesterolemia, smoking, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, male aged >40 yr)

-Use with caution in severe impairment

-Partial vision loss and blindness  have been reported with use of 5-HT1 agonists

-Vasospasm-related events

Points of recommendation

-Clear diagnosis of migraine headache must be established

-Overuse of acute migraine drugs (eg, ergotamine, triptans, opioids, or combination of these drugs for ≥10 days/month) may lead to exacerbation of headache (medication overuse headache)

-May increased blood pressure, monitor

Pregnancy level


There are no adequate data on developmental risk associated with use in pregnant women. Published data have suggested that women with migraines may be at increased risk of preeclampsia during pregnancy.

Breast feeding warning

There are no data on presence of frovatriptan in human milk, effects of frovatriptan on breastfed infant, or effects of on milk production. Developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from frovatriptan or underlying maternal condition.

Related drugs

Almotriptan , eletriptan

Drug forms

Frova, Migard

Ask a Pharmacist

User's questions
    No comments yet.